Journal Club Articles
Journal Club
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, M.D., M.B.A. abou-alg@mskcc.org, George Lau, M.D., F.R.C.P., Masatoshi Kudo, M.D., Ph.D., Stephen L. Chan, M.D., Robin Kate Kelley, M.D., Junji Furuse, M.D., Ph.D., Wattana Sukeepaisarnjaroen, M.D., +24 for the HIMALAYA Investigator
Journal Club
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer
These findings suggest that the combination of pembrolizumab with bevacizumab and metronomic cyclophosphamide has clinical activity with a favorable toxicity profile in treatment of recurrent ovarian cancer.